ArticleMedical oncology (Northwood, London, England)2013
Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03320421 (Phase II Trial of Hypofractionated Whole-breast Radiation and Concomitant Boost to the Surgical Bed After Breast Conserving Surgery), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Hypofractionated Whole-breast Radiation and Concomitant Boost to the Surgical Bed After Breast Conserving Surgery
Who cites it
21 citing papers in PubMed.
- Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial.International journal of radiation oncology, biology, physics · 2016Trial
- Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial.Journal of cancer research and clinical oncology · 2014Trial
- Comparison of simultaneous integrated tumor bed boost and sequential boost during hypofractionated whole-breast irradiation after breast-conserving surgery.Clinical and translational radiation oncology · 2025Article
- Comprehensive analysis of dosimetry correlation and clinical outcomes in image-guided brachytherapy vs. intensity-modulated radiotherapy photon boost after whole breast hypofractionated radiation in post-breast conserving surgery: A 5-year median follow-up data from a tertiary care institution in India.Journal of contemporary brachytherapy · 2025Article
- Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study.Biomedicines · 2022Article
- Hypofractionation and Concomitant Boost in Ductal Carcinoma In Situ (DCIS): Analysis of a Prospective Case Series with Long-Term Follow-Up.Life (Basel, Switzerland) · 2022Article
- Accelerated hypofractionated breast radiotherapy with simultaneous integrated boost: a feasibility study.Radiation oncology journal · 2022Article
- Long-term results of hypofractionation with concomitant boost in patients with early breast cancer: A prospective study.PloS one · 2021Article
- Intensity-Modulated Radiotherapy with Concomitant Boost After Breast Conserving Surgery: A Phase I-II Trial.Breast cancer (Dove Medical Press) · 2020Article
- Do hypofraction and large breast size reciprocally fit in breast cancer radiotherapy?Annals of translational medicine · 2019Article
- De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients.Medical oncology (Northwood, London, England) · 2018Review
- Volumetric modulated arc therapy (VMAT) to deliver nodal irradiation in breast cancer patients.Medical oncology (Northwood, London, England) · 2017Observational
- Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer.Medical oncology (Northwood, London, England) · 2017Article
- Hypofractionation with no boost after breast conservation in early-stage breast cancer patients.Medical oncology (Northwood, London, England) · 2016Article
- Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence.Breast care (Basel, Switzerland) · 2015Review
- Does accelerated hypofractionated adjuvant whole-breast radiotherapy increase mammographic density or change mammographic features?The British journal of radiology · 2015Article
- Frontiers in radiotherapy for early-stage invasive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Review
- Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case series.Medical oncology (Northwood, London, England) · 2014Article
- The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists.Medical oncology (Northwood, London, England) · 2013Article
- Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): a prospective case series.Journal of cancer research and clinical oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accelerated hypofractionation (HF) using larger dose per fraction, delivered in fewer fractions over a shorter overall treatment time, is presently a consistent possibility for adjuvant whole breast radiation (WBRT) after breast-conserving surgery for early breast cancer (EBC). Between 2005 and 2008, we submitted 375 consecutive patients to accelerated hypofractionated WBRT after breast-conserving surgery for EBC. The basic course of radiation consisted of 45 Gy in 20 fractions over 4 weeks to the whole breast (2.25 Gy daily) with an additional daily concomitant boost of 0.25 Gy up to 50 Gy to the surgical bed. Overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS) and local control (LC) were assessed. Late toxicity was scored according to the CTCAE v3.0; acute toxicity using the RTOG/EORTC toxicity scale. Cosmesis was assessed comparing treated and untreated breast. Quality of life (QoL) was determined using EORTC QLQ-C30/QLQ-BR23 questionnaires. With a median follow-up of 60 months (range 42-88), 5 years OS, CSS, DFS and LC were 97.6, 99.4, 96.6 and 100 %, respectively. Late skin and subcutaneous toxicity was generally mild, with few events > grade 2 observed. Cosmetic results were excellent in 75.7 % of patients, good in 20 % and fair in 4.3 %. QoL, assessed both through QLQ-C30/QLQ-BR23, was generally favorable, within the functioning and symptoms domains. Our study is another proof of principle that HF WBRT with a concurrent boost dose to the surgical cavity represents a safe and effective postoperative treatment modality with excellent local control and survival, consistent cosmetic results and mild toxicity.
Indexed as
Identifiers
23460537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.